131I Metaiodobenzylguanidine Therapy of Pheochromocytoma

嗜铬细胞瘤是一种能够合成和分泌儿茶酚胺的嗜铬细胞肿瘤。本项目测试了~(131)I-间碘苯甲基胍(131I-MIBG)放射毒性治疗恶性嗜铬细胞瘤的疗效，特别是测试了治疗前的“增敏”是否增加了~(131)I-MIBG治疗在减少肿瘤大小和数量以及肿瘤负担方面的疗效。中心假设是，在恶性嗜铬细胞瘤患者中，131I-MIBG治疗可以摧毁肿瘤细胞，从而减少肿瘤的大小和数量，并减少肿瘤负担；而且，增敏程序增强了131I-MIBG的疗效。这一新的方案仍需要FDA的一些澄清，因此，到目前为止还没有患者被纳入这项研究。

Pheochromocytomas are tumors of chromaffin cells that synthesize and secrete catecholamines. This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-metaiodobenzylguanidine (131I-MIBG), and in particular tests whether pre-treatment "sensitization" increases the efficacy of 131I-MIBG treatment in reducing the size and number of tumors and the tumor burden. The central hypothesis is that in patients with malignant pheochromocytoma, treatment with 131I-MIBG destroys tumor cells and thereby decreases the size and number of tumors and the tumor burden; and that the "sensitization" procedures augment the effectiveness of 131I-MIBG. This new protocol still needs some clarifications from the FDA, therefore, no patients have been enrolled into the study so far.